EPO Issues Patent To Sunesis Pharma Voreloxin Combination

Voreloxin is an anticancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer, where as Cytarabine is the standard-of-care treatment for Acute Myeloid Leukemia (AML).

Additonally, Sunesis is planning to start a multinational, randomised, double-blind, placebo-controlled, pivotal Phase 3 clinical trial of Voreloxin in combination with Cytarabine in a relapsed/refractory AML patient population in the second half of this year.

Sunesis said that following the validation process, it will provide patent coverage for such combination products in 30 member states of the European Patent Convention, including the major European markets, through 2025.

Daniel Swisher, CEO of Sunesis, said:”This patent is an important new addition to our intellectual property estate, as it covers the combination of Voreloxin and Cytarabine, the contemplated initial market application.

“We are pursuing a strategy to provide exclusive coverage in the Voreloxin patent estate out to 2030. Beyond our granted patents, we have filed patent applications covering formulations, combination uses, dosing, manufacturing processes and composition of matter claims. We look forward to the successful prosecution of these patent applications in multiple territories around the world.”